The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global biopharmaceutical manufacturing market reached a volume of 6 Million Liters in 2019. The manufacturing of biopharmaceuticals (biopharma) is characterized by a highly complex research and development (R&D) setting, which includes the use of technologies that are harnessed by new scientific advances. The production process of biopharmaceuticals supports a wide range of production-related, highly specialized jobs. Some of these employments include packaging and filling machine operators and tenders, blending and mixing machine setters, and testers, inspectors, samplers, sorters, and chemical equipment operators. Different methods can be deployed for the production of biopharmaceuticals, which include continuous and follow-on manufacturing systems. In the continuous system, raw materials are fed continuously from one end into the process and the finished product is extracted from the other end. On the other hand, the follow-on product development mostly includes the adoption of both current and legacy bioprocessing technologies to obtain a cost-effective procedure to make drugs.
With the emergence of the industrial revolution 4.0, biopharma manufacturers have been increasingly using a digitized paradigm that involves machines to collect, process and produce data, then communicate it with other machines through the Industrial Internet of Things (IIoT). These next-generation technologies have helped industry players to increase process understanding with the provision of more data with advanced modeling techniques and analytics. Besides this, expansion in the biopharma industry has led to the emerging trend of outsourcing due to high costs, and lack of expertise in in-house manufacturing. As a result, contract manufacturing organizations (CMOs) are investing heavily to expand their existing capabilities and capacities. Most of these firms are based across developed regions. However, the advent of advanced manufacturing methods and technologies in emerging economies, like India and China, has led to a significant shift in the market. Also, the industry currently accounts for a sophisticated, specialized and highly regulated field with outsized economic contributions across the globe. Looking forward, IMARC Group expects the global biopharmaceutical manufacturing market exhibit moderate growth during the next five years.
Breakup by Cell Culture:
At present, mammalian cell culture is the largest segment in the market.
Breakup by Class:
Amongst the above-mentioned categories, recombinant proteins dominate the market.
Currently, North America is the biggest market, accounting for the majority of the total market share.
The report has also analyzed the competitive landscape of the market, with some of the key players being F. Hoffmann-La Roche Ltd, Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Groupe Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, and Biogen Inc.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at